Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.

Area of Science:

• Critical Care Medicine
• Pharmacology
• Infectious Diseases

Background:

• Clinical trial results on higher-dose anticoagulation for COVID-19 have been inconsistent.
• The optimal anticoagulation strategy for hospitalized COVID-19 patients remains under investigation.

Purpose of the Study:

• To evaluate the association between higher- versus lower-dose anticoagulation and clinical outcomes in COVID-19 patients.
• To synthesize evidence from randomized trials to inform treatment guidelines.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials.
• Identified trials from WHO ICTRP and ClinicalTrials.gov, including those with no restriction on language or trial status.
• Extracted data on all-cause mortality, ventilation/death, thromboembolic events, and major bleeding.

Main Results:

• Therapeutic-dose heparin anticoagulation significantly reduced 28-day mortality compared to prophylactic doses (OR 0.77).
• Mortality rates were similar between intermediate- and prophylactic-dose anticoagulation.
• Higher-dose anticoagulation was associated with fewer thromboembolic events but a greater risk of major bleeding.

Conclusions:

• Therapeutic-dose anticoagulation with heparins appears beneficial in reducing mortality for hospitalized COVID-19 patients.
• The balance between reduced mortality and increased bleeding risk with higher-dose anticoagulation requires careful clinical judgment.
• Further research may be needed to precisely define optimal dosing strategies across different patient subgroups.